Prosecution Insights
Prosecution Insights
18 pending office actions • 11 art units • 16 examiners • 0 of 18 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 9 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 9 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 6 (33%) |
| §112 only | 1 (6%) |
| Double-patenting only | 2 (11%) |
| Double-patenting + other | 4 (22%) |
| Multi-statute (no §101) | 4 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 2 | 67.9% | +31.6% |
| NIEBAUER, RONALD T | 2 | 41.1% | +33.7% |
| HUTTER, GILLIAN A | 1 | 54.2% | +46.9% |
| WESTERBERG, NISSA M | 1 | 23.3% | +36.8% |
| KOSTURKO, GEORGE W | 1 | 54.7% | +48.6% |
| SCHMITT, MICHAEL J | 1 | 56.6% | +21.7% |
| CHEN, PO-CHIH | 1 | 74.3% | +14.4% |
| JOHNSON, NICOLE F | 1 | 87.5% | +7.2% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| MULLINS, JESSICA LYNN | 1 | 50.0% | +35.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707320 | PHOTODYNAMIC THERAPY ILLUMINATOR DEVICES AND METHODS | JOHNSON, NICOLE F | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278583 | DEXAMETHASONE FOR TREATMENT OF BLEPHARITIS | KIDWELL, MICHELE M | 156d overdue |
| 19294542 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | HUTTER, GILLIAN A | 9d overdue |
| 19273752 | ORAL FORMULATIONS OF DEURUXOLITINIB | WESTERBERG, NISSA M | 40d |
| 18683943 | STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF | SCOTLAND, REBECCA LYNN | 70d |
| 18666084 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | CHEN, PO-CHIH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002478 | LONG ACTING GLP-1/GIP DUAL AGONISTS | NIEBAUER, RONALD T | 125d overdue |
| 17981237 | PHOTODYNAMIC THERAPY ILLUMINATOR DEVICES AND METHODS | MULLINS, JESSICA LYNN | 51d overdue |
| 18078571 | DEUTERATED DERIVATIVES OF RUXOLITINIB | MOORE, SUSANNA | 31d overdue |
| 19294542 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | HUTTER, GILLIAN A | 9d overdue |
| 19273752 | ORAL FORMULATIONS OF DEURUXOLITINIB | WESTERBERG, NISSA M | 40d |
| 18905925 | DEUTERATED DERIVATIVES OF RUXOLITINIB | MOORE, SUSANNA | — |
| 18755253 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | KOSTURKO, GEORGE W | — |
| 18731580 | DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF | SCHMITT, MICHAEL J | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1621 | 2 |
| 1658 | 2 |
| 1615 | 2 |
| 1625 | 1 |
| 1618 | 1 |
| 3796 | 1 |
| 3792 | 1 |
| 1613 | 1 |
| 3781 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19294542 | METHODS OF TREATMENT OF JAK INHIBITION RESPONSIVE CONDITIONS WITH DEUTERATED JAK INHIBITORS | HUTTER, GILLIAN A | 1625 | §101§102§103DP | Final Rejection | 9d overdue | Pending | Aug 08, 2025 |
| 19273752 | ORAL FORMULATIONS OF DEURUXOLITINIB | WESTERBERG, NISSA M | 1618 | §103§112Other | Final Rejection | 40d | Pending | Jul 18, 2025 |
| 18905925 | DEUTERATED DERIVATIVES OF RUXOLITINIB | MOORE, SUSANNA | 1624 | §103 | Final Rejection | — | Pending | Oct 03, 2024 |
| 18755253 | TREATMENT OF HAIR LOSS DISORDERS WITH DEUTERATED JAK INHIBITORS | KOSTURKO, GEORGE W | — | DP | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18731580 | DEUTERATED ANALOGS OF D-SERINE AND USES THEREOF | SCHMITT, MICHAEL J | — | §102§103DP | Non-Final OA | — | Pending | Jun 03, 2024 |
| 18666084 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS | CHEN, PO-CHIH | 1621 | §102§103Other | Final Rejection | — | Pending | May 16, 2024 |
| 18707320 | PHOTODYNAMIC THERAPY ILLUMINATOR DEVICES AND METHODS | JOHNSON, NICOLE F | 3796 | §103 | Non-Final OA | — | Pending | May 03, 2024 |
| 18013380 | METHODS AND INTERMEDIATES FOR PREPARING JAK INHIBITORS | O DELL, DAVID K | 1621 | §103 | Final Rejection | — | Pending | Dec 28, 2022 |
| 18078571 | DEUTERATED DERIVATIVES OF RUXOLITINIB | MOORE, SUSANNA | 1624 | §103 | Final Rejection | 31d overdue | Pending | Dec 09, 2022 |
| 17981237 | PHOTODYNAMIC THERAPY ILLUMINATOR DEVICES AND METHODS | MULLINS, JESSICA LYNN | 3792 | §103 | Final Rejection | 51d overdue | Pending | Nov 04, 2022 |
| 18812726 | LONG ACTING GLP-1/GIP DUAL AGONISTS | NIEBAUER, RONALD T | 1658 | §103§112DP | Non-Final OA | — | Pending | Aug 22, 2024 |
| 18705130 | METHOD OF INJECTING DIHYDROERGOTAMINE INTO THE BODY | ULSH, DUNG T | — | DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18683943 | STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF | SCOTLAND, REBECCA LYNN | 1615 | §103§112Other | Non-Final OA | 70d | Pending | Feb 15, 2024 |
| 18683932 | STABLE CYCLOSPORINE OPHTHALMIC FORMULATION AND MANUFACTURING PROCESS THEREOF | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112DPOther | Non-Final OA | 70d | Pending | Feb 15, 2024 |
| 18278583 | DEXAMETHASONE FOR TREATMENT OF BLEPHARITIS | KIDWELL, MICHELE M | 3781 | §102§103§112 | Non-Final OA | 156d overdue | Pending | Aug 23, 2023 |
| 18317625 | MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION OF QUETIAPINE | MERCIER, MELISSA S | 1615 | §103 | Final Rejection | 104d overdue | Pending | May 15, 2023 |
| 18002478 | LONG ACTING GLP-1/GIP DUAL AGONISTS | NIEBAUER, RONALD T | 1658 | §103§112DP | Non-Final OA | 125d overdue | Pending | Dec 19, 2022 |
| 17603921 | Methods for Treatment of Subjects with Psoriatic Arthritis | FORD, VANESSA L | 1674 | §112 | Non-Final OA | — | Pending | Oct 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial